オプションチェーンは、Bristol-Myers Squibbの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Bristol-Myers Squibbの市場センチメントを評価します。.

Bristol-Myers Squibb (OTC:BMYMP) 株価情報, オプションチェーン

Bristol-Myers Squibb

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

BRISTOL-MYERS SQUIBB $2PR by Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co

News

Guidance

Coca-Cola Sees FY25 Adj. EPS Growth 2%-3%, Sees FY25 Free Cash Flow (Ex. Fairlife Payment) ~$9.5B

USA Compression Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USAC#NYSE">USAC</a>) reported quarterly earnings of $0.18 per share which missed the analyst consensus estimate of $0.24 by 25 percent. This is a 800 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $245.900 million which beat the analyst consensus estimate of $243.460 million by 1.00 percent. This is a 9.27 percent increase over sales of $225.049 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

USAC

USA Compression Partners Q4 2024 GAAP EPS $0.18 Misses $0.24 Estimate, Sales $245.900M Beat $243.460M Estimate

Buybacks

PSFE

Paysafe Board Authorizes Additional $70M To Existing Share Repurchase Program

On Monday, the U.S. District Court for the District of Massachusetts temporarily blocked the National Institutes of Health (NIH) from cutting research funding in 22 states.
What Happened: On Friday, under updated guidelines, NIH said it would now <a target="_blank" href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-25-068.html" rel="noreferrer noopener">apply</a> a standard indirect cost rate of 15% to all new and existing grants, replacing the previous practice of negotiating separate rates for each grant.
Historically, NIH's average indirect cost rate has been around 27%–28%, with some institutions charging over 50% or even 60%.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump's Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
In 2023, NIH awarded over $35 billion in research funding across nearly 50,000 grants. Of this, $26 billion went directly to research, while $9 billion covered indirect costs.
By implementing a 15% rate, NIH aligns more closely with private research funders. Many private foundations, including the Bill &amp; Melinda Gates Foundation, cap indirect costs at 10%–15%, while some do not cover indirect costs at all.
Why It Matters: NIH has a $48 billion budget and 27 institutes that fund critical research on diseases like <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42222191/donald-trump-nominates-pandemic-critic-jay-bhattacharya-tapped-to-reshape-national-institutes-of-health-that-oversees-budget-of-48-billion" rel="noreferrer noopener">cancer and diabetes</a>. The funding cuts were to take effect on Monday, 10 February.
In a social media post, NIH <a target="_blank" href="https://x.com/NIH/status/1888004759396958263?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet&amp;mx=2" rel="noreferrer noopener">said</a> the change would save the federal government $4 billion annually. It said three schools that had charged more than 60% in indirect rates—Harvard University, Yale University, and Johns Hopkins University—had multibillion-dollar endowments.
A complaint <a target="_blank" href="https://coag.gov/app/uploads/2025/02/ECF-001-Complaint-Mass.-v.-NIH-1.pdf" rel="noreferrer noopener">filed</a> earlier on Monday argued that "Without relief from NIH's action, these institutions' cutting-edge work to cure and treat human disease will grind to a halt."
The lawsuit also mentioned, "In issuing the Rate Change Notice, the NIH has also acted beyond its statutory authority and has failed to promulgate the change using notice and comment rulemaking."
The lawsuit adds, "The Rate Change Notice is arbitrary and capricious in, among other ways, its failure to articulate the bases for the categorical rate cap of 15%, its failure to consider the grant recipients' reliance on their negotiated rates, and its disregard for the factual findings that formed the bases for the currently operative negotiated indirect cost rates."
The NIH action will "devastate critical public health research at universities and research institutions," the lawsuit claims.
The complaint alleges that the agency's action will result in layoffs, suspension of clinical trials, disruption of ongoing research programs, and laboratory closures.
Judge Angel Kelley of the U.S. District Court for the District of Massachusetts <a target="_blank" href="https://fingfx.thomsonreuters.com/gfx/legaldocs/gdpzkzwrwvw/02102025nih_order.pdf" rel="noreferrer noopener">issued</a> a temporary restraining order asking the 22 states to file a status report in 24 hours and again every two weeks to confirm the regular disbursement of the funds. The judge set a hearing for 21 February.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/02/43608591/taiwan-semiconductors-trillion-dollar-valuation-the-chipmaker-enabling-ai-boom" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor's Trillion-Dollar Valuation: The Chipmaker Enabling AI Boom</a></li>
</ul>
Image via Shutterstock

Biotech

Government

Health Care

General

iShares Dow Jones US Pharmaceuticals Index Fund

iShares Dow Jones US Health Care Provides Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

PowerShares Dynamic Healthcare Sector Portfolio

US States Sue National Institutes Of Health Over $4 Billion Annual Cut In Biomedical Research Grant Budget

The transaction includes reseller and merchant contracts, as well as dedicated technology and employees related to the business. The consideration for this transaction largely consists of annual earnout payments over the next five years. The transaction is expected to close in 30 days subject to finalizing certain transition services-related items.
 &nbsp;

Asset Sales

Paysafe Inks Definitive Deal To Sell Its Direct Marketing Payment Processing Business Line; No Terms Disclosed

Coca-Cola Q4 2024 Adj. EPS $0.55 Beats $0.52 Estimate, Sales $11.5B Beat $10.677B Estimate

THRD

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) is trading 3.8% lower in pre-market on Tuesday ahead of its second-quarter earnings call scheduled today after the market close.
What Happened: The company&#8217;s management is likely to provide updates on the delayed filing of its annual report for the fiscal year ending June 30, 2024, during the earnings call today. The shares of SMCI surged 17.5% on Monday, a day before its earnings release.
The Nasdaq Exchange has permitted SMCI to submit its 10-K filing until Feb. 25. The San Jose, California-based artificial intelligence company risks delisting if it misses the deadline.
In July, Ernst &amp; Young (EY), then serving as Super Micro&#8217;s auditor, expressed concerns about the company&#8217;s governance and internal controls over financial reporting, prompting the board to establish a special committee. In December, Super Micro issued a statement regarding the special committee being unable to discover material facts backing EY&#8217;s statements, adding that there were no significant concerns regarding the integrity of Super Micro&#8217;s management. Previously, SMCI CEO Charles Liang expressed confidence that the technology company&#8217;s stock will not be delisted from the Nasdaq.
SEE ALSO: <a href="https://www.benzinga.com/news/earnings/25/02/43600652/super-micro-computer-q2-earnings-preview-accounting-updates-nasdaq-deadline-on-watch">Super Micro Computer Q2 Earnings Preview: Accounting Updates, Nasdaq Deadline On Watch</a>
Why It Matters: <a href="https://www.benzinga.com/news/earnings/25/02/43600652/super-micro-computer-q2-earnings-preview-accounting-updates-nasdaq-deadline-on-watch">Wall Street is keenly observing</a> SMCI&#8217;s ongoing accounting issues. Investors are also eager for communication from the company regarding improvements to its financial controls and transparency. This is crucial to reassure shareholders about its governance practices, especially in light of the potential delisting risk.
In a note, Wedbush analyst, Matt Bryson, stated that they believe Supermicro may successfully restate its financials or could also seek a 180-day extension. However, they expressed uncertainty about Super Micro Computer&#8217;s near-term performance, pointing out that competitors such as HP Enterprise (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) have secured contracts in the artificial intelligence server market.
Bryson has expressed reservations about the company&#8217;s current stock price, citing &#8220;substantial unknowns&#8221; that could negatively impact the share price in the future.
However, Loop Capital Markets analyst&nbsp;Ananda Baruah&nbsp;is upbeat on SMCI and considers it an "important company in an important space" poised to benefit from growth factors like overcoming SEC filing delays and maintaining strong fundamentals.
SMCI stock has plunged more than 44% over the past year.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43591520/dell-vs-hp-ai-server-jpmorgan-pick">Wall Street&#8217;s AI Server Darling? JPMorgan Says It&#8217;s Still Dell</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Tech

SMCI

SMCI Stock Falls Nearly 4% In Tuesday Pre-Market As Investors Await An Update On Delayed Filing

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Buy and maintains $16 price target.

Price Target

Reiteration

Analyst Ratings

ESPR

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target

Mizuho analyst John Baumgartner maintains Hain Celestial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAIN#NASDAQ">HAIN</a>) with a Neutral and lowers the price target from $7 to $4.5.

HAIN

Mizuho Maintains Neutral on Hain Celestial Group, Lowers Price Target to $4.5

DA Davidson analyst Matt Summerville downgrades Columbus McKinnon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCO#NASDAQ">CMCO</a>) from Buy to Neutral and announces $35 price target.

Downgrades

CMCO

DA Davidson Downgrades Columbus McKinnon to Neutral, Announces $35 Price Target

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) with a Buy and raises the price target from $80 to $115.

CORT

HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $115

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

Kiora Gets Approval To Begin KLARITY, A Phase 2 Clinical Trial To Investigate KIO-104 In Patients With Retinal Macular Edem

BP PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) shares are trading lower after <a href="https://www.bp.com/content/dam/bp/business-sites/en/global/corporate/pdfs/investors/bp-fourth-quarter-2024-results.pdf" target="_blank" rel="noreferrer noopener">the </a>company reported fourth-quarter results.
Sales and other operating revenues came in at&nbsp;$45.752 billion, missing the consensus of&nbsp;$47.511 billion.
Hydrocarbon production was 850 mboe/d (-5.4% Y/Y), with underlying production declining&nbsp;2.7% Y/Y mainly due to base decline in Egypt.
The Renewables pipeline stood at 60.6GW (bp net), including a 38.7GW bp net share from Lightsource bp&#8217;s (LSbp&#8217;s) pipeline in the quarter.&nbsp;
Adjusted EBITDA declined to&nbsp;$8.41 billion from&nbsp;$10.57 billion a year ago.&nbsp;Underlying RC profit per American Depositary Share (ADS) came in at&nbsp;$0.44,<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener"> missing the consensus of&nbsp;$0.47.&nbsp;</a>
Operating cash flow was&nbsp;$7.43 billion, compared to&nbsp;$9.38 billion in the prior-year quarter.&nbsp;
Capital expenditure was&nbsp;$3.73 billion versus&nbsp;$4.71 billion a year ago.&nbsp;Net debt rose to&nbsp;$23.0 billion from&nbsp;$20.9 billion a year ago.
Chief executive officer Murray Auchincloss said, &#8220;We have been reshaping our portfolio &#8211; sanctioning new major projects, and focusing our low-carbon investment &#8211; and we have made strong progress in reducing costs. Building on the actions taken in the last 12 months, we now plan to fundamentally reset our strategy and drive further improvements in performance, all in service of growing cash flow and returns.&#8221;
Kate Thomson, Chief Financial Officer, stated, &#8220;During the year, we introduced our target to deliver at least $2 billion of savings(a) by the end of 2026 relative to 2023 and are making strong progress, achieving $0.8 billion of structural cost reduction. We raised the dividend per ordinary share by 10% and delivered $7 billion of share buybacks.&#8221;
Related: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43608991/bp-set-to-report-q4-earnings-as-elliot-management-builds-stake" rel="noreferrer noopener">BP Set To Report Q4 Earnings As Elliot Management Builds Stake: Declining Margins, Revenues In The Spotlight</a>
Dividend: BP disclosed an interim dividend of 8.000 cents per ordinary share, payable on March 28, 2025. Holders of ADSs are expected to receive&nbsp;$0.48 per ADS.
Repurchase: The company completed previously announced&nbsp;$1.75 billion in share buybacks during the quarter.
Furthermore, BP plans to conduct a&nbsp;$1.75 billion&nbsp;share buyback before its&nbsp;first-quarter&nbsp;earnings release.
Elliott Management, a U.S.-based activist hedge fund managing approximately $70 billion in assets, reportedly acquired a stake in BP. The fund advocates for substantial changes at the British oil <a target="_blank" href="https://www.benzinga.com/news/large-cap/25/02/43591241/whats-going-on-with-oil-giant-bp-stock-today" rel="noreferrer noopener">company to boost its performance</a>.
First-Quarter FY25&nbsp;Outlook: BP anticipates upstream production to be lower than the&nbsp;fourth quarter&nbsp;of 2024.
In its customer business, BP projects seasonally lower volumes sequentially, with fuel margins likely remaining sensitive to supply cost fluctuations.
In the products segment, BP expects refining margins to stay low in the&nbsp;first quarter and expects a lower level of refinery turnaround activity compared to the fourth quarter of 2024.
FY25&nbsp;Guidance: BP&nbsp;expects reported upstream production to be lower and underlying upstream production to be&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">slightly lower than the prior year</a>.&nbsp;
It anticipates divestments and other proceeds to be around $3 billion&nbsp;for the year, with weighted towards the second half.
BP anticipates approximately $3 billion in divestment and other proceeds in 2025, primarily in the second half.
With $22 billion realized since the second quarter of 2020, the company remains on track to achieve its $25 billion target for the 2020-2025 period.
The company sees Gulf of America settlement payments for the year to be about $1.2 billion&nbsp;pre-tax, including&nbsp;$1.1 billion&nbsp;pre-tax to be paid during the&nbsp;second quarter.
Yesterday, BP inked a contract with Oil and Natural Gas Corporation Limited (ONGC), as per which bp will serve as the Technical Services Provider (<a target="_blank" href="https://www.bp.com/en/global/corporate/news-and-insights/press-releases/ongc-and-bp-sign-contract-to-enhance-production-from-mumbai-high.html" rel="noreferrer noopener">TSP</a>) for the Mumbai High field, India&#8217;s largest and most prolific offshore oil field.
Investors can gain exposure to the stock via&nbsp;Texas Capital Texas Oil Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OILT#NYSE">OILT</a>) and Abacus FCF Real Assets Leaders ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ABLD#BATS">ABLD</a>).
Price Action: BP shares are trading lower by 0.67% at $34.19 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43614105/activist-investor-elliott-builds-25-billion-stake-in-phillips-66-pressures-for-midstream-spinoff-report" target="_blank" rel="noreferrer noopener">Activist Investor Elliott Builds $2.5 Billion Stake In Phillips 66, Pressures For Midstream Spinoff: Report</a></li>
</ul>
Photo: Jon Lyall via Shutterstock.

Equities

Large Cap

ABLD

OILT

BP Q4 Results: Lower Revenue, Rising Debt, CEO Pledges Fundamental Strategy Shift And More

HC Wainwright &amp; Co. analyst Scott Buck reiterates Mitek Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MITK#NASDAQ">MITK</a>) with a Buy and maintains $13 price target.

MITK

HC Wainwright & Co. Reiterates Buy on Mitek Systems, Maintains $13 Price Target

Travel

Travelers Companies Sees $1.7 billion Pre-tax Losses Relating To The January 2025 California Wildfires

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fisglobal.com%2F&amp;esheet=54203542&amp;newsitemid=20250211419904&amp;lan=en-US&amp;anchor=FIS&amp;index=1&amp;md5=d6b7c456ff60084466ef02824ba6d642">FIS</a><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fisglobal.com%2F&amp;esheet=54203542&amp;newsitemid=20250211419904&amp;lan=en-US&amp;anchor=%26%23174%3B&amp;index=2&amp;md5=12565643be68b6daf87725dd4438c846">&#xAE;</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>), a global leader in financial technology, today announced a new strategic partnership with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.affirm.com%2F&amp;esheet=54203542&amp;newsitemid=20250211419904&amp;lan=en-US&amp;anchor=Affirm&amp;index=3&amp;md5=6577b18686c487227bae496b2e437929">Affirm</a>, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>), the payment network that can empower consumers and help merchants drive growth, making Affirm its integrated pay-over-time provider for debit issuers. Together, FIS and Affirm will deliver a new program that enables FIS' vast network of banking clients to integrate Affirm's industry-leading solution into their existing debit program via their digital banking and mobile app platforms, allowing their customers to easily manage their finances in a single place.
This collaboration is well-timed, as banks are searching for new and innovative options to meet consumer needs and demands for flexible purchasing solutions. This program offers a substantial opportunity for financial institutions to provide a sought-after pay-over-time solution to the millions of U.S. consumers who have a debit card. By integrating Affirm's offering into banking products, FIS continues to unlock growth opportunities for clients across the money lifecycle, help meet the demands of the growing market and strategically position financial institutions to capitalize on the offering's potential by fostering customer loyalty and accelerating growth.

AFRM

FIS Partners With Affirm to Bring Pay-Over-Time Option to Debit Card Users

On Tuesday, Inspira Technologies OXY B.H.N. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IINN#NASDAQ">IINN</a>) announced <a target="_blank" href="https://www.benzinga.com/profile/inspira-technologies" rel="noreferrer noopener">positive initial results</a> from its previously reported collaboration with Ennocure MedTech to develop a novel bio-electronic treatment for preventing bloodstream infections.
In ex-vivo porcine skin model testing, the bio-electronic patch demonstrated a 95% reduction in bacterial presence within 4 hours, with continued effectiveness observed over 24 hours.
The technology, which uses physical electric stimulation rather than chemical agents, showed promising results in preventing pathogen growth on treated surfaces.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43596316/mondaycom-q4-earnings-beats-estimates-with-32-revenue-growth-ceo-highlights-ai-as-a-game-changer-for-2025" rel="noreferrer noopener">Monday.com Beats Q4 Earnings Estimates, Boasts 32% Revenue Growth: CEO Calls AI A Game-Changer</a>
Inspira Technologies chief Dagi Ben-Noon noted an estimated 250,000 bloodstream infections related to intravenous lines occurring worldwide yearly. The approach could offer significant advantages in critical care settings.
Bio-electronic technology can address several key challenges associated with traditional IV dressings, including prevention of bacterial growth through physical rather than chemical means, potential for extended wear time, reduced frequency of dressing changes, applicability to both skin surface and cannula areas, and real-time monitoring capabilities.
Price Action: IINN stock is down 3.35% at $0.8206 premarket at last check on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/02/43593383/tower-semiconductor-q4-earnings-beats-eps-estimates-expands-ai-chip-production-for-2025-growth" target="_blank" rel="noreferrer noopener">Tower Semiconductor Q4 Earnings: Beats EPS Estimates, Expands AI Chip Production For 2025 Growth, Stock Falls As Outlook Disappoints The Street</a></li>
</ul>

Market-Moving Exclusives

Exclusives

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

EXCLUSIVE: Inspira and Ennocure's Bio-Electronic Tech Uses Electric Stimulation to Help Prevent IV-Related Infections

Here are three stocks with buy rank and strong value characteristics for investors to consider today, February 11th:
OMV Aktiengesellschaft OMVKY: This energy and chemicals company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.5% over the last 60 days.
<div class="chart_embed">
<h3>OMV AG Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/OMVKY/price-consensus-chart?icid=chart-OMVKY-price-consensus-chart"><img alt="OMV AG Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/f0/1739262717.png" style="height:264px; width:527px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/OMVKY/price-consensus-chart?icid=chart-OMVKY-price-consensus-chart">OMV AG price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/OMVKY?icid=chart-OMVKY-price-consensus-chart">OMV AG Quote</a>
</div>
OMV has a price-to-earnings ratio (P/E) of 5.96, compared with 7.30 for the industry. The company possesses a <a href="https://www.zacks.com/style-scores-education/">Value Score</a>&nbsp; of A.
<div class="chart_embed">
<h3>OMV AG PE Ratio (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ttm#NYSE">TTM</a>)</h3>
<a href="https://www.zacks.com/stock/chart/OMVKY/fundamental/pe-ratio-ttm?icid=chart-OMVKY-fundamental/pe-ratio-ttm">TTM</a>)&quot; height=&quot;250&quot; src=&quot;https://staticx-tuner.zacks.com/images/charts/c9/1739262943.png&quot; title=&quot;&quot; width=&quot;493&quot; /&gt;
<a href="https://www.zacks.com/stock/chart/OMVKY/fundamental/pe-ratio-ttm?icid=chart-OMVKY-fundamental/pe-ratio-ttm">OMV AG pe-ratio-ttm</a> | <a href="https://www.zacks.com/stock/quote/OMVKY?icid=chart-OMVKY-fundamental/pe-ratio-ttm">OMV AG Quote</a>
</div>
Pacira BioSciences, Inc. PCRX: This non-opioid pain management and regenerative health solutions company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its next year earnings increasing 21% over the last 60 days.
<div class="chart_embed">
<h3>Pacira BioSciences, Inc. Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/PCRX/price-consensus-chart?icid=chart-PCRX-price-consensus-chart"><img alt="Pacira BioSciences, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/18/1739262729.png" style="height:264px; width:568px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/PCRX/price-consensus-chart?icid=chart-PCRX-price-consensus-chart">Pacira BioSciences, Inc. price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/PCRX?icid=chart-PCRX-price-consensus-chart">Pacira BioSciences, Inc. Quote</a>
</div>
Pacira has a price-to-earnings ratio (P/E) of 7.69, compared with 24.45 for the S&amp;P 500. The company possesses a Value Score of A.
<div class="chart_embed">
<h3>Pacira BioSciences, Inc. PE Ratio (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ttm#NYSE">TTM</a>)</h3>
<a href="https://www.zacks.com/stock/chart/PCRX/fundamental/pe-ratio-ttm?icid=chart-PCRX-fundamental/pe-ratio-ttm">TTM</a>)&quot; height=&quot;250&quot; src=&quot;https://staticx-tuner.zacks.com/images/charts/35/1739262962.png&quot; title=&quot;&quot; width=&quot;527&quot; /&gt;
<a href="https://www.zacks.com/stock/chart/PCRX/fundamental/pe-ratio-ttm?icid=chart-PCRX-fundamental/pe-ratio-ttm">Pacira BioSciences, Inc. pe-ratio-ttm</a> | <a href="https://www.zacks.com/stock/quote/PCRX?icid=chart-PCRX-fundamental/pe-ratio-ttm">Pacira BioSciences, Inc. Quote</a>
</div>
EZCORP, Inc. EZPW: This pawn services company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.2% over the last 60 days.
<div class="chart_embed">
<h3>EZCORP, Inc. Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/EZPW/price-consensus-chart?icid=chart-EZPW-price-consensus-chart"><img alt="EZCORP, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/f4/1739262742.png" style="height:264px; width:568px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/EZPW/price-consensus-chart?icid=chart-EZPW-price-consensus-chart">EZCORP, Inc. price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/EZPW?icid=chart-EZPW-price-consensus-chart">EZCORP, Inc. Quote</a>
</div>
Ezcorp has a price-to-earnings ratio (P/E) of 10.33, compared with 15.30 for the industry. The company possesses a Value Score of A.
<div class="chart_embed">
<h3>EZCORP, Inc. PE Ratio (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ttm#NYSE">TTM</a>)</h3>
<a href="https://www.zacks.com/stock/chart/EZPW/fundamental/pe-ratio-ttm?icid=chart-EZPW-fundamental/pe-ratio-ttm">TTM</a>)&quot; height=&quot;251&quot; src=&quot;https://staticx-tuner.zacks.com/images/charts/b8/1739262981.png&quot; title=&quot;&quot; width=&quot;532&quot; /&gt;
<a href="https://www.zacks.com/stock/chart/EZPW/fundamental/pe-ratio-ttm?icid=chart-EZPW-fundamental/pe-ratio-ttm">EZCORP, Inc. pe-ratio-ttm</a> | <a href="https://www.zacks.com/stock/quote/EZPW?icid=chart-EZPW-fundamental/pe-ratio-ttm">EZCORP, Inc. Quote</a>
</div>
&nbsp;
See <a href="https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&amp;ICID=zpi%20_1link">the full list of top ranked stocks here.</a>
&nbsp;
Learn more about the <a href="https://www.zacks.com/education/stock-scorecard/value-trading">Value score and how it is calculated here.</a>
&nbsp;
<h2>Only $1 to See All Zacks&#39; Buys and Sells</h2>
We&#39;re not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like&nbsp;Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.
<a href="https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/6328?adid=SYND_BENZ_ZU_ZU_ZACKS1RANKADDITIONS_268_02112025_2413286&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286" style="font-weight:bold">See Stocks Now &gt;&gt;</a>
&nbsp;
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. <a href="https://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&amp;ADID=SYND_BENZ_7BEST_ZACKS1RANKADDITIONS_268_2413286&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286" target="_blank">Click to get this free report</a>

&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=EZPW&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_268_2413286_EZPW&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286">EZCORP, Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/ezpw#NASDAQ">EZPW</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=PCRX&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_268_2413286_PCRX&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286">Pacira BioSciences, Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/pcrx#NASDAQ">PCRX</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=OMVKY&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_268_2413286_OMVKY&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286">OMV AG (OMVKY): Free Stock Analysis Report</a>
<a href="https://www.zacks.com/commentary/2413286/best-value-stocks-to-buy-for-february-11th?cid=CS-BENZ-FT-zacks_1_rank_additions|value_additions-2413286">To read this article on Zacks.com click here.</a>
<a href="https://www.zacks.com/">Zacks Investment Research</a>

Small Cap

EZPW

PCRX

Best Value Stocks To Buy For February 11th

EXCLUSIVE: Inspira Technologies Tells Benzinga 'Initial ex-vivo testing demonstrates significant bacterial reduction potential for innovative IV dressing technology aimed at preventing bloodstream infections'

Comments

Bristol-Myers Squibb

Bristol-Myers Squibb (BMYMP) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル